IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0654776
(2007-01-18)
|
등록번호 |
US-8367609
(2013-02-05)
|
발명자
/ 주소 |
- Detmar, Michael
- Kajiya, Kentaro
|
출원인 / 주소 |
- The General Hospital Corporation
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
13 |
초록
This application features methods of treating (e.g., reducing, ameliorating, or preventing) skin damage (e.g., induced by UVB) by decreasing the level or activity of VEGF-A, e.g., in the skin, of a subject.
대표청구항
▼
1. A method of inhibiting ultraviolet B (UVB)-induced skin damage in a subject, the method comprising: administering to the skin of the subject prior to or during UVB light exposure a vascular endothelial growth factor (VEGF)-A antagonist in an amount sufficient to promote lymphatic function in the
1. A method of inhibiting ultraviolet B (UVB)-induced skin damage in a subject, the method comprising: administering to the skin of the subject prior to or during UVB light exposure a vascular endothelial growth factor (VEGF)-A antagonist in an amount sufficient to promote lymphatic function in the skin of the subject; andadministering to the skin of the subject prior to or during UVB light exposure a VEGF-C polypeptide in an amount sufficient to promote lymphatic function in the skin of the subject,wherein the promotion of lymphatic function in the skin of the subject inhibits UVB-induced skin damage in the subject. 2. The method of claim 1, wherein the subject is human. 3. The method of claim 1, wherein the VEGF-A antagonist is administered prior to UVB light exposure. 4. The method of claim 1, wherein the VEGF-A antagonist is administered during UVB light exposure. 5. The method of claim 1, wherein the VEGF-C polypeptide is administered prior to UVB light exposure. 6. The method of claim 1, wherein the VEGF-C polypeptide is administered during UVB light exposure. 7. The method of claim 1, wherein the VEGF-A antagonist and the VEGF-C polypeptide are administered prior to UVB light exposure. 8. The method of claim 1, wherein the VEGF-A antagonist and the VEGF-C polypeptide are administered during UVB light exposure. 9. The method of claim 1, wherein the administration of the VEGF-A antagonist is topical, intramuscular, intraperitoneal, subcutaneous, or intravenous administration. 10. The method of claim 1, wherein the administration of the VEGF-C polypeptide is topical, intramuscular, intraperitoneal, subcutaneous, or intravenous administration. 11. The method of claim 1, wherein the VEGF-A antagonist and the VEGF-C polypeptide are administered together in a single composition. 12. The method of claim 11, wherein the composition is administered by topical, intramuscular, intraperitoneal, subcutaneous, or intravenous administration. 13. The method of claim 11, wherein the composition further comprises a moisturizer, a sunscreen, or both. 14. The method of claim 11, wherein the composition is formulated as a solution, cream, ointment, gel, lotion, shampoo, soap, or aerosol. 15. The method of claim 1, wherein the VEGF-A antagonist is administered in a composition comprising the VEGF-A antagonist. 16. The method of claim 15, wherein the composition further comprises a moisturizer, a sunscreen, or both. 17. The method of claim 15, wherein the composition is formulated as a solution, cream, ointment, gel, lotion, shampoo, soap, or aerosol. 18. The method of claim 1, wherein the VEGF-C polypeptide is administered in a composition comprising the VEGF-C polypeptide. 19. The method of claim 18, wherein the composition further comprises a moisturizer, a sunscreen, or both. 20. The method of claim 18, wherein the composition is formulated as a solution, cream, ointment, gel, lotion, shampoo, soap, or aerosol.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.